Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada-Reference-Cited by-同舟云学术

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Published:2023-08-02 Issue:12 Volume:37 Page:F25-F35
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Costiniuk Cecilia T.¹²³,Singer Joel⁴⁵⁶,Lee Terry⁵⁶,Galipeau Yannick⁷,McCluskie Pauline S.⁷,Arnold Corey⁷,Langlois Marc-André⁷,Needham Judy⁵⁶,Jenabian Mohammad-Ali⁸,Burchell Ann N.⁹¹⁰,Samji Hasina¹¹¹²,Chambers Catharine¹⁰¹³,Walmsley Sharon¹⁴,Ostrowski Mario¹⁵,Kovacs Colin¹⁶,Tan Darrell H.S.¹³¹⁴¹⁷,Harris Marianne¹⁸,Hull Mark¹⁸,Brumme Zabrina L.¹¹¹⁸,Lapointe Hope R.¹⁸,Brockman Mark A.¹¹¹⁸¹⁹,Margolese Shari⁵,Mandarino Enrico⁵,Samarani Suzanne¹,Vulesevic Branka⁵²⁰,Lebouché Bertrand¹²²¹²²,Angel Jonathan B.⁷²⁰,Routy Jean-Pierre¹²²³,Cooper Curtis L.²⁰,Anis Aslam H.⁴⁵⁶,

Affiliation:

1. Division of Infectious Diseases/Chronic Viral Illness Service, McGill University Health Centre, Royal Victoria Hospital

2. Infectious Diseases and Immunity in Global Health Research Program, Research Institute of McGill University Health Centre

3. Department of Experimental Medicine, McGill University, Montreal, Québec

4. School of Population and Public Health, University of British Columbia

5. CIHR Canadian HIV Trials Network (CTN)

6. Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia

7. Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario

8. Department of Biological Sciences, Université du Québec à Montréal, Montreal, Québec

9. Department of Family and Community Medicine, St Michael's Hospital, Unity Health Toronto

10. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario

11. Faculty of Health Sciences, Simon Fraser University, Burnaby

12. British Columbia Centre for Disease Control, Vancouver, British Columbia

13. MAP Centre for Urban Health Solutions, St Michael's Hospital

14. Division of Infectious Diseases, Department of Medicine, University of Toronto

15. Clinical Sciences Division and Department of Immunology, University of Toronto, Li Ka Shing Knowledge Institute, St. Michael's Hospital

16. Maple Leaf Medical Clinic

17. Institute of Public Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario

18. British Columbia Centre for Excellence in HIV/AIDS, Vancouver

19. Department of Molecular Biology and Biochemistry, Faculty of Science, Simon Fraser University, Burnaby, British Columbia

20. Division of Infectious Diseases, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Ontario

21. Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University

22. Canadian Institutes of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials

23. Division of Hematology, Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.

Abstract

Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses. Design: In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month). Methods: COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutralization assay for Ancestral (Wuhan), Delta and Omicron (BA.1) spike variants. Univariable and multivariable quantile regression were used to compare COVID-19-specific antibody neutralization capacity by HIV status. Results: Neutralization assays were performed on 256 PWH and 256 controls based on specimen availability at the timepoint of interest, having received two vaccines and known date of vaccination. There was a significant interaction between HIV status and previous COVID-19 infection status in median ID50. There were no differences in median ID50 for HIV+ vs. HIV-negative persons without past COVID-19 infection. For participants with past COVID-19 infection, median ICD50 was significantly higher in controls than in PWH for ancestral SARS-CoV-2 and Omicron variants, with a trend for the Delta variant in the same direction. Conclusion: Vaccine-induced SARS-CoV-2 neutralization capacity was similar between PWH vs. HIV-negative persons without past COVID-19 infection, demonstrating favourable humoral-mediated immunogenicity. Both HIV+ and HIV-negative persons demonstrated hybrid immunity. Trial registration: clinicaltrials.gov NCT04894448.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference31 articles.

1. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state;Tesoriero;JAMA Netw Open,2021

2. Racial/ethnic and income disparities in the prevalence of comorbidities that are associated with risk for severe COVID-19 among adults receiving HIV Care, United States, 2014-2019;Weiser;J Acquir Immune Defic Syndr,2021

3. Vaccinations for the HIV-infected adult: a review of the current recommendations, part I;Crum-Cianflone;Infect Dis Ther,2017

4. Vaccinations for the HIV-infected adult: a review of the current recommendations, part II;Crum-Cianflone;Infect Dis Ther,2017

5. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial;Bergman;EBioMedicine,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size;2023-10-09